Now the shares of Allscripts Healthcare Solutions, Inc. The firm now has $13.00 price target on the software maker's stock, down from their prior price target of $15.00. MDRX has been the subject of several research analyst reports. They …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MDRX at https://www.zacks.com/ap/MDRX
CNBC16d
Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) has bounced back in the market after posting mixed first quarter results that spooked investors. The stock came crashing by 2.29% to lows of $13.01 a share on posting revenues of …
Additionally, the net loss includes an $11 million charge for the accretion of redemption preference on the redeemable convertible preferred stock, issued in conjunction with the Netsmart transaction in April 2016. Non-GAAP net income …
Allscripts (NASDAQ:MDRX) and GoodRx have partnered to deliver a new solution ... Register now to create your own custom streaming stock watchlist. NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes. All other quotes …
In the report, ISI Group noted, “We have downgraded our rating on MDRX from Buy to Neutral following the recent stock
10/29/2013 8,932 Derivative/Non-derivative trans. at $14.22 per share. 127,014
Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) CEO Paul Black sold 15,000 shares of Allscripts Healthcare Solutions stock in a transaction on Wednesday, March 30th. The shares were sold at an average price of $13.31, for a …
Search Skip to Navigation Skip to Main Content Skip to Related Content 0
FibroGen (FGEN +5.76%) lost over 2% in after-hours trading after it announced that it intends to offer and sell up to $300 million of its common stock in an underwritten follow-on offering. Allscripts Healthcare Solutions (MDRX +0.47%) …